Brachytherapy, a form of radiation therapy in which a radiation source is implanted next to the area requiring treatment, is at the core of CivaTech Oncology®, Research Triangle Park, N.C., products. The company’s second low-dose rate (LDR) implantable device, CivaSheet™, has received clearance from the Food and Drug Administration (FDA) for use in treatment of a variety of cancers. The CivaSheet encapsulates LDR palladium in a bioabsorbable polymer-based membrane. The small, flat dots of palladium on the sheet can be custom-fitted to direct the optimal amount of radiation to a specific patient’s cancer—while protecting healthy tissue from collateral damage.
FDA approves low-dose radiation implant
What's New? | December 29, 2014 | By: ATA
You might also like...
Textile researchers prepare stem cells to become organ tissue
Smart fabric responds to both temperature and electricity
New method to create engineered silk announced
Magnetic biomedical devices can pop into shape as needed
New polymers could enable better wearable devices